Biotime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.22	Brooklyn ImmunoTherapeutics CEO Quits, Names Interim Replacement; Andrew Jackson Is New CFO (RTTNews)
15.09.21	Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts (PR Newswire)
15.11.19	Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program (Businesswire)
12.11.19	Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update (Businesswire)
05.11.19	Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 (Businesswire)
28.10.19	Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019 (Businesswire)
23.10.19	Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting (Businesswire)
22.10.19	Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019 (Businesswire)
14.10.19	Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting (Businesswire)
07.10.19	Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019 (Businesswire)
30.09.19	Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019 (Businesswire)
26.09.19	Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 (Businesswire)
25.09.19	Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans (Businesswire)
23.09.19	Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 (Businesswire)
19.09.19	Lineage Cell Therapeutics Receives CE Mark Approval for Renevia® (Businesswire)
06.08.19	Ausblick: Biotime vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
31.07.19	BioTime Announces Name Change to Lineage Cell Therapeutics (Businesswire)
11.07.19	BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System (Businesswire)
02.07.19	BioTime Conducts Sale of Shares in OncoCyte Corporation (Businesswire)
22.05.19	BioTime Announces Appointment of General Counsel (Businesswire)
10.05.19	BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen® (Businesswire)
09.05.19	BioTime Reports First Quarter 2019 Financial Results and Provides Business Update (Businesswire)
07.05.19	Ausblick: Biotime stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
06.05.19	BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury (Businesswire)
03.05.19	BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 (Businesswire)
02.05.19	BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (Businesswire)
26.04.19	BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference (Businesswire)
16.04.19	BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) (Businesswire)
18.03.19	BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019 (Businesswire)
14.03.19	BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update (Businesswire)
12.03.19	Ausblick: Biotime legt Zahlen zum jüngsten Quartal vor (finanzen.net)
11.03.19	BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company (Businesswire)
07.03.19	BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019 (Businesswire)
04.03.19	BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 (Businesswire)
02.01.19	BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019 (Businesswire)
04.12.18	BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke (Businesswire)
29.11.18	BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 (Businesswire)
09.11.18	NantKwest Turning Heads, AUTL To Report Data In Dec., PTLA Marches Ahead (RTTNews)
08.11.18	BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company (Businesswire)
08.11.18	BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update (Businesswire)
06.11.18	BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call (Businesswire)
06.11.18	Ausblick: Biotime stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
05.11.18	BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd. (Businesswire)
30.10.18	BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018 (Businesswire)
29.10.18	BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting (Businesswire)
25.10.18	BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares (Businesswire)
22.10.18	BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th (Businesswire)
27.09.18	BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences (Businesswire)
25.09.18	BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies (Businesswire)
21.09.18	BioTime Warrants to Expire on October 1, 2018 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	81.32	1.78 %	K V
Kuehne+Nagel Int	207.00	1.17 %	K V
Lonza Grp	583.40	0.52 %	K V
Swiss Life Hldg	734.60	0.38 %	K V
Zurich Insur Gr	539.00	0.22 %	K V
Part Grp Hldg	1’377.50	-0.25 %	K V
Alcon	80.64	-0.32 %	K V
Nestle	73.88	-0.40 %	K V
ABB	53.18	-0.71 %	K V
Sonova Hldg	313.20	-1.66 %	K V

Nachrichten zu Biotime IncShs

Aktien Top/Flop

Meistgelesene Nachrichten